Drugs / NYH817G
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04262739 | Dec 2019 → Dec 2021 | cancer | Haim Bio Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NYH817G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04262739 ↗ |
| Route | Oral | “Subject will orally administer NYH817G (15 mg) during the cycles(21 days)” NCT04262739 ↗ |